Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the commencement of commercial supplies under its recently announced Rs. 825 crore CDMO (Contract Development and Manufacturing Organization) mandate. The first commercial dispatch, valued at approximately Rs. 50 crore, was completed during the first quarter of fiscal year 2026-27 (Q1FY2026-27). This milestone signifies the successful transition from the validation and qualification phase to the commercial execution stage of the mandate.
Management Commentary on the Milestone
Commenting on the development, Mr. Sanjay Suri, Managing Director of Morepen Laboratories Limited, stated, "This is an important milestone in Morepen's transition toward long-duration global manufacturing partnerships. Our teams have worked closely with the customer through validation, manufacturing readiness and supply-chain planning. Having started execution of commercial supplies, we are focused on scaling up, expanding capacity and building a stronger CDMO platform across additional customer and product opportunities."
Scaling Plans for Q2FY2026-27
Following the initial dispatch, Morepen expects to scale the program further in the coming quarter. Additional supplies of approximately Rs. 225 crore are anticipated during Q2FY2026-27, subject to customer schedules and regulatory or commercial requirements. The company is also strengthening its manufacturing infrastructure to support larger CDMO opportunities. Total reactor capacity is projected to reach approximately 600 kiloliters (KL) by the end of Q2, with further expansion toward 800 KL and 1,000 KL in subsequent phases.
Strategic Implications for Morepen
The commencement of commercial supplies under this mandate reinforces Morepen's strategy to build a scalable CDMO platform, deepen customer partnerships, and participate in long-duration global manufacturing opportunities. The company continues to enhance its manufacturing, research, and regulatory capabilities to support growth across both domestic and international markets.
About Morepen Laboratories
Morepen Laboratories Limited is a pharmaceutical and healthcare company with a diversified presence across active pharmaceutical ingredients (APIs), finished formulations, diagnostics, and consumer healthcare. The company is focused on strengthening its manufacturing and regulatory infrastructure to support sustained growth.
Safe Harbour Statement
Certain statements in this release concerning future prospects, business plans, expectations, and performance may be forward-looking statements. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. The company does not undertake to update any forward-looking statements except as required by applicable law.
